 NEWARK, Calif., Sept. 17, 2021 PRNewswire -- Protagonist Therapeutics, Inc. Nasdaq: PTGX Protagonist or the Company today announced the receipt of a verbal communication from the U.S. Food and Drug Administration FDA that Protagonists clinical studies for rusfertide, an investigational product candidate currently in development, have been placed on a clinical hold. 